WellingMed Completes Hundreds of Millions of yuan Series B Financing
WellingMed (Beijing) Co., Ltd. (Chinese: 微岩医学科技（北京）有限公司) recently completed series B financing of hundreds of millions of yuan, jointly invested by Galaxy Innovation Capital (Chinese: 银河创新资本), Haier Capital (Chinese: 海尔资本), and Hunan Pharmaceutical Development Private Equity Fund (Chinese: 湖南医药发展私募基金).
The funds will be mainly used for new product development and registration, as well as the construction of Pathogenic Microorganism Skynet Laboratory (Chinese: 病原微生物天网实验室).
In November 2021, WellingMed announced the completion of series A financing of 100 million yuan, jointly invested by Runda Medical (Chinese: 润达医疗) and Gongshu State Investment (Chinese: 拱墅国投). Founded in 1999, Runda Medical is dedicated to providing integrated medical laboratory services covering both solutions and a full range of IVD products. It is listed on Shanghai Stock Exchange and has annual revenues of RMB 8.9 billion in 2021.
WellingMed is a national high-tech enterprise based on molecular biology technology platform, focusing on accurate diagnosis of clinical infection. The core technical personnel are from Tsinghua University, Peking University, and the Chinese Academy of Sciences. Based on the three cutting-edge technologies of next-generation sequencing (NGS), microfluidic chips, and transcriptome sequencing, it has independently developed and launched a variety of IVD products such as automated testing instruments, software, and testing reagents.
WellingMed will cooperate with Runda Medical, independent clinical laboratories, and hospitals to build more than 100 lab centers in the next three years, realizing metagenomic next-generation sequencing (mNGS) technology for rapid detection of complex infections with a new pattern of pathogenic microorganism Skynet laboratory.
